RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer

RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer

Abstract Background As systemic therapy for metastatic breast cancer (BC) improves, the survival benefit from hormonal and targeted therapy urges treatment of brain metastases (BMs) with minimal toxicity and less systemic therapy interruption. Here we assessed clinical outcomes in BC patients who re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology advances 2021-08, Vol.3 (Supplement_3), p.iii21-iii22
Hauptverfasser: Wang, Yan, An, Ran, Wang, Fuchenchu, Gao, Chao, Raghavendra, Akshara Singareeka, Kim, Yon Son Betty, Briere, Tina Marie, Amaya, Diana N, Li, Jing
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page iii22
container_issue Supplement_3
container_start_page iii21
container_title Neuro-oncology advances
container_volume 3
creator Wang, Yan
An, Ran
Wang, Fuchenchu
Gao, Chao
Raghavendra, Akshara Singareeka
Kim, Yon Son Betty
Briere, Tina Marie
Amaya, Diana N
Li, Jing
description Abstract Background As systemic therapy for metastatic breast cancer (BC) improves, the survival benefit from hormonal and targeted therapy urges treatment of brain metastases (BMs) with minimal toxicity and less systemic therapy interruption. Here we assessed clinical outcomes in BC patients who received upfront stereotactic radiosurgery (SRS). Methods We identified 236 patients who received upfront SRS with/without surgery for BMs from metastatic BC from 06/2007 to 05/2018. Twenty-four patients who received SRS for surgical cavity were excluded for analysis. Overall survival (OS) and salvage radiation-free survival (SRFS) were estimated using Kaplan-Meier analysis. Cox proportional hazard regression was used to identify prognostic factors. Results At a median follow-up time of 15.4 months (range, 0.8–119.6), the estimated median OS was 18.5 mo (95% CI, 14.9–21). Factors associated with OS on multivariate analysis (MVA) were molecular subtypes (12.2 months for triple-negative [n=68], 13.3 months for HR+/HER2- [n=66], 36.4 months for HR+/HER2+ [n=46], and 28.1 months for HER2+ [n=32], p=0.002), KPS >80 (p
doi_str_mv 10.1093/noajnl/vdab071.088
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_noajnl_vdab071_088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/noajnl/vdab071.088</oup_id><sourcerecordid>10.1093/noajnl/vdab071.088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1258-2a61806450a2d76f0f71caef998212316d5f1c1f5941f96be5efe5fdf3b3baa33</originalsourceid><addsrcrecordid>eNqNkMtqwzAQRUVpoSHND3SlH3Cih-XIy5C-AoFCH2szljTFIbHCyA7k76uSLrosDMzcy9y7OIzdSzGXotaLPsKu3y9OHlqxlHNh7RWbqEqrQpW1vf5z37JZSjshhDKlKYWasPFt9bAppJ3z95FO3Qn2HHrPfZcCpMBd7AeK2cMhEB-PSNngKYsQB3BD5ziB72Ia6SvQmWMk3hJ0PT-EAVKekHgOHbKbCwfuoHeB7tgNwj6F2e-ess-nx4_1S7F9fd6sV9vCSWVsoaCSVlSlEaD8skKBS-kgYF1bJZWWlTconURTlxLrqg0mYDDoUbe6BdB6ytSl11FMiQI2R-oOQOdGiuaHXXNh1_yyazK7HCouoTge__P_DXj7do8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer</title><source>Oxford Open</source><source>PubMed Central</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Wang, Yan ; An, Ran ; Wang, Fuchenchu ; Gao, Chao ; Raghavendra, Akshara Singareeka ; Kim, Yon Son Betty ; Briere, Tina Marie ; Amaya, Diana N ; Li, Jing</creator><creatorcontrib>Wang, Yan ; An, Ran ; Wang, Fuchenchu ; Gao, Chao ; Raghavendra, Akshara Singareeka ; Kim, Yon Son Betty ; Briere, Tina Marie ; Amaya, Diana N ; Li, Jing</creatorcontrib><description>Abstract Background As systemic therapy for metastatic breast cancer (BC) improves, the survival benefit from hormonal and targeted therapy urges treatment of brain metastases (BMs) with minimal toxicity and less systemic therapy interruption. Here we assessed clinical outcomes in BC patients who received upfront stereotactic radiosurgery (SRS). Methods We identified 236 patients who received upfront SRS with/without surgery for BMs from metastatic BC from 06/2007 to 05/2018. Twenty-four patients who received SRS for surgical cavity were excluded for analysis. Overall survival (OS) and salvage radiation-free survival (SRFS) were estimated using Kaplan-Meier analysis. Cox proportional hazard regression was used to identify prognostic factors. Results At a median follow-up time of 15.4 months (range, 0.8–119.6), the estimated median OS was 18.5 mo (95% CI, 14.9–21). Factors associated with OS on multivariate analysis (MVA) were molecular subtypes (12.2 months for triple-negative [n=68], 13.3 months for HR+/HER2- [n=66], 36.4 months for HR+/HER2+ [n=46], and 28.1 months for HER2+ [n=32], p=0.002), KPS &gt;80 (p&lt;0.0001), receipt of chemotherapy (p=0.016) or anti-HER2 therapy (p=0.029) after diagnosis of BM, and type of salvage radiation (p&lt;0.0001). OS was comparable in patients who received upfront SRS to less or more than 4 lesions (19.3 months for &lt;4 [n=162] vs. 17.8 months for &gt;/= 4 [n=50], p=0.36). The 12-month salvage RT rate was 25% for WBRT and 26.4% for SRS. The median SRFS was 7.4 months (95% CI, 6.5‒8.3). Factors associated with SRFS on MVA were subtypes (p=0.002), KPS (p=0.011), and receipt of hormone therapy after diagnosis of BM (p=0.031). Conclusions The median OS for BC patients who developed BM is over 15 months. Molecular subtypes (HER2+ and HR+/HER2+), good KPS, and anti-HER2 or hormone therapy predicted better OS and SRFS. Prospective studies are needed to verify these results and refine the best treatment strategies for these patients.</description><identifier>ISSN: 2632-2498</identifier><identifier>EISSN: 2632-2498</identifier><identifier>DOI: 10.1093/noajnl/vdab071.088</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology advances, 2021-08, Vol.3 (Supplement_3), p.iii21-iii22</ispartof><rights>The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,865,27926,27927</link.rule.ids></links><search><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>An, Ran</creatorcontrib><creatorcontrib>Wang, Fuchenchu</creatorcontrib><creatorcontrib>Gao, Chao</creatorcontrib><creatorcontrib>Raghavendra, Akshara Singareeka</creatorcontrib><creatorcontrib>Kim, Yon Son Betty</creatorcontrib><creatorcontrib>Briere, Tina Marie</creatorcontrib><creatorcontrib>Amaya, Diana N</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><title>RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer</title><title>Neuro-oncology advances</title><description>Abstract Background As systemic therapy for metastatic breast cancer (BC) improves, the survival benefit from hormonal and targeted therapy urges treatment of brain metastases (BMs) with minimal toxicity and less systemic therapy interruption. Here we assessed clinical outcomes in BC patients who received upfront stereotactic radiosurgery (SRS). Methods We identified 236 patients who received upfront SRS with/without surgery for BMs from metastatic BC from 06/2007 to 05/2018. Twenty-four patients who received SRS for surgical cavity were excluded for analysis. Overall survival (OS) and salvage radiation-free survival (SRFS) were estimated using Kaplan-Meier analysis. Cox proportional hazard regression was used to identify prognostic factors. Results At a median follow-up time of 15.4 months (range, 0.8–119.6), the estimated median OS was 18.5 mo (95% CI, 14.9–21). Factors associated with OS on multivariate analysis (MVA) were molecular subtypes (12.2 months for triple-negative [n=68], 13.3 months for HR+/HER2- [n=66], 36.4 months for HR+/HER2+ [n=46], and 28.1 months for HER2+ [n=32], p=0.002), KPS &gt;80 (p&lt;0.0001), receipt of chemotherapy (p=0.016) or anti-HER2 therapy (p=0.029) after diagnosis of BM, and type of salvage radiation (p&lt;0.0001). OS was comparable in patients who received upfront SRS to less or more than 4 lesions (19.3 months for &lt;4 [n=162] vs. 17.8 months for &gt;/= 4 [n=50], p=0.36). The 12-month salvage RT rate was 25% for WBRT and 26.4% for SRS. The median SRFS was 7.4 months (95% CI, 6.5‒8.3). Factors associated with SRFS on MVA were subtypes (p=0.002), KPS (p=0.011), and receipt of hormone therapy after diagnosis of BM (p=0.031). Conclusions The median OS for BC patients who developed BM is over 15 months. Molecular subtypes (HER2+ and HR+/HER2+), good KPS, and anti-HER2 or hormone therapy predicted better OS and SRFS. Prospective studies are needed to verify these results and refine the best treatment strategies for these patients.</description><issn>2632-2498</issn><issn>2632-2498</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkMtqwzAQRUVpoSHND3SlH3Cih-XIy5C-AoFCH2szljTFIbHCyA7k76uSLrosDMzcy9y7OIzdSzGXotaLPsKu3y9OHlqxlHNh7RWbqEqrQpW1vf5z37JZSjshhDKlKYWasPFt9bAppJ3z95FO3Qn2HHrPfZcCpMBd7AeK2cMhEB-PSNngKYsQB3BD5ziB72Ia6SvQmWMk3hJ0PT-EAVKekHgOHbKbCwfuoHeB7tgNwj6F2e-ess-nx4_1S7F9fd6sV9vCSWVsoaCSVlSlEaD8skKBS-kgYF1bJZWWlTconURTlxLrqg0mYDDoUbe6BdB6ytSl11FMiQI2R-oOQOdGiuaHXXNh1_yyazK7HCouoTge__P_DXj7do8</recordid><startdate>20210809</startdate><enddate>20210809</enddate><creator>Wang, Yan</creator><creator>An, Ran</creator><creator>Wang, Fuchenchu</creator><creator>Gao, Chao</creator><creator>Raghavendra, Akshara Singareeka</creator><creator>Kim, Yon Son Betty</creator><creator>Briere, Tina Marie</creator><creator>Amaya, Diana N</creator><creator>Li, Jing</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20210809</creationdate><title>RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer</title><author>Wang, Yan ; An, Ran ; Wang, Fuchenchu ; Gao, Chao ; Raghavendra, Akshara Singareeka ; Kim, Yon Son Betty ; Briere, Tina Marie ; Amaya, Diana N ; Li, Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1258-2a61806450a2d76f0f71caef998212316d5f1c1f5941f96be5efe5fdf3b3baa33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>An, Ran</creatorcontrib><creatorcontrib>Wang, Fuchenchu</creatorcontrib><creatorcontrib>Gao, Chao</creatorcontrib><creatorcontrib>Raghavendra, Akshara Singareeka</creatorcontrib><creatorcontrib>Kim, Yon Son Betty</creatorcontrib><creatorcontrib>Briere, Tina Marie</creatorcontrib><creatorcontrib>Amaya, Diana N</creatorcontrib><creatorcontrib>Li, Jing</creatorcontrib><collection>Oxford Open</collection><collection>CrossRef</collection><jtitle>Neuro-oncology advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yan</au><au>An, Ran</au><au>Wang, Fuchenchu</au><au>Gao, Chao</au><au>Raghavendra, Akshara Singareeka</au><au>Kim, Yon Son Betty</au><au>Briere, Tina Marie</au><au>Amaya, Diana N</au><au>Li, Jing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer</atitle><jtitle>Neuro-oncology advances</jtitle><date>2021-08-09</date><risdate>2021</risdate><volume>3</volume><issue>Supplement_3</issue><spage>iii21</spage><epage>iii22</epage><pages>iii21-iii22</pages><issn>2632-2498</issn><eissn>2632-2498</eissn><abstract>Abstract Background As systemic therapy for metastatic breast cancer (BC) improves, the survival benefit from hormonal and targeted therapy urges treatment of brain metastases (BMs) with minimal toxicity and less systemic therapy interruption. Here we assessed clinical outcomes in BC patients who received upfront stereotactic radiosurgery (SRS). Methods We identified 236 patients who received upfront SRS with/without surgery for BMs from metastatic BC from 06/2007 to 05/2018. Twenty-four patients who received SRS for surgical cavity were excluded for analysis. Overall survival (OS) and salvage radiation-free survival (SRFS) were estimated using Kaplan-Meier analysis. Cox proportional hazard regression was used to identify prognostic factors. Results At a median follow-up time of 15.4 months (range, 0.8–119.6), the estimated median OS was 18.5 mo (95% CI, 14.9–21). Factors associated with OS on multivariate analysis (MVA) were molecular subtypes (12.2 months for triple-negative [n=68], 13.3 months for HR+/HER2- [n=66], 36.4 months for HR+/HER2+ [n=46], and 28.1 months for HER2+ [n=32], p=0.002), KPS &gt;80 (p&lt;0.0001), receipt of chemotherapy (p=0.016) or anti-HER2 therapy (p=0.029) after diagnosis of BM, and type of salvage radiation (p&lt;0.0001). OS was comparable in patients who received upfront SRS to less or more than 4 lesions (19.3 months for &lt;4 [n=162] vs. 17.8 months for &gt;/= 4 [n=50], p=0.36). The 12-month salvage RT rate was 25% for WBRT and 26.4% for SRS. The median SRFS was 7.4 months (95% CI, 6.5‒8.3). Factors associated with SRFS on MVA were subtypes (p=0.002), KPS (p=0.011), and receipt of hormone therapy after diagnosis of BM (p=0.031). Conclusions The median OS for BC patients who developed BM is over 15 months. Molecular subtypes (HER2+ and HR+/HER2+), good KPS, and anti-HER2 or hormone therapy predicted better OS and SRFS. Prospective studies are needed to verify these results and refine the best treatment strategies for these patients.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/noajnl/vdab071.088</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2632-2498
ispartof Neuro-oncology advances, 2021-08, Vol.3 (Supplement_3), p.iii21-iii22
issn 2632-2498
2632-2498
language eng
recordid cdi_crossref_primary_10_1093_noajnl_vdab071_088
source Oxford Open; PubMed Central; Directory of Open Access Journals; EZB Electronic Journals Library
title RADI-18. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T16%3A17%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RADI-18.%20Survival%20and%20disease%20control%20after%20upfront%20stereotactic%20radiosurgery%20for%20brain%20metastases%20from%20breast%20cancer&rft.jtitle=Neuro-oncology%20advances&rft.au=Wang,%20Yan&rft.date=2021-08-09&rft.volume=3&rft.issue=Supplement_3&rft.spage=iii21&rft.epage=iii22&rft.pages=iii21-iii22&rft.issn=2632-2498&rft.eissn=2632-2498&rft_id=info:doi/10.1093/noajnl/vdab071.088&rft_dat=%3Coup_cross%3E10.1093/noajnl/vdab071.088%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/noajnl/vdab071.088&rfr_iscdi=true